or Try an Advanced Search...

    Technical Analysis for EDIT - Editas Medicine, Inc.

    Grade Last Price % Change Price Change
    F 2.91 0.34% 0.01
    EDIT closed up 0.34 percent on Friday, November 1, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    6 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical EDIT trend table...
    Date Alert Name Type % Chg
    Doji - Bullish? Reversal 0.00%
    Earnings Movers Other 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 0.34%
    New 52 Week Low Weakness 0.34%
    Stochastic Reached Oversold Weakness 0.34%
    Down 3 Days in a Row Weakness 0.34%
    Oversold Stochastic Weakness 0.34%
    MACD Bearish Signal Line Cross Bearish -3.64%
    20 DMA Resistance Bearish -6.43%
    Older End-of-Day Signals for EDIT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 17 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Up 3% about 21 hours ago
    Up 2% about 22 hours ago
    Up 1% about 22 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    EDIT Chart by TradingView
    Basic chart:

    Profile

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Immune System Genetics Enzymes Genetic Engineering Genome CRISPR DNA Genome Editing Cas9

    Is EDIT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?
    Oct 28 Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
    Oct 25 Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline
    Oct 24 Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
    Oct 23 EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
    Oct 22 Editas and Genevant team up to develop gene editing therapies
    Oct 22 EDIT Editas_Medicine_Strategic_Update_-_October_2024_-_FINAL
    Oct 22 Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
    Oct 22 EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
    Oct 22 Editas reviews path for gene editing therapy to save costs
    See more EDIT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.69
    52 Week Low 2.9
    Average Volume 1,927,550
    200-Day Moving Average 5.54
    50-Day Moving Average 3.46
    20-Day Moving Average 3.21
    10-Day Moving Average 3.18
    Average True Range 0.21
    RSI (14) 37.50
    ADX 15.73
    +DI 20.32
    -DI 24.04
    Chandelier Exit (Long, 3 ATRs) 3.18
    Chandelier Exit (Short, 3 ATRs) 3.52
    Upper Bollinger Bands 3.59
    Lower Bollinger Band 2.83
    Percent B (%b) 0.11
    BandWidth 23.84
    MACD Line -0.14
    MACD Signal Line -0.12
    MACD Histogram -0.0237
    Fundamentals Value
    Market Cap 237.67 Million
    Num Shares 81.7 Million
    EPS -2.69
    Price-to-Earnings (P/E) Ratio -1.08
    Price-to-Sales 25.99
    Price-to-Book 1.69
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.11
    Resistance 3 (R3) 3.12 3.08 3.07
    Resistance 2 (R2) 3.08 3.03 3.07 3.06
    Resistance 1 (R1) 2.99 3.00 2.97 2.98 3.05
    Pivot Point 2.95 2.95 2.94 2.94 2.95
    Support 1 (S1) 2.86 2.90 2.84 2.85 2.77
    Support 2 (S2) 2.82 2.87 2.81 2.76
    Support 3 (S3) 2.73 2.82 2.75
    Support 4 (S4) 2.72